Merle M. Schanz

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral Therapy.

Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral Therapy.

Journal: The Journal of infectious diseases

Published: September 18, 2024

Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines.

Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines.

Journal: Cell reports. Medicine

Published: February 26, 2024

Assessing immunogenicity barriers of the HIV-1 envelope trimer.

Assessing immunogenicity barriers of the HIV-1 envelope trimer.

Journal: NPJ vaccines

Published: April 12, 2023

Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland.

Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland.

Journal: BMJ open

Published: July 27, 2021

Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity.

Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity.

Journal: Nature communications

Published: April 14, 2021

Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools.

Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools.

Journal: BMJ (Clinical research ed.)

Published: March 18, 2021

Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?

Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?

Journal: Retrovirology

Published: May 18, 2018

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.

Journal: Nature

Published: February 12, 2018

Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.

Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.

Journal: The Journal of experimental medicine

Published: February 06, 2018

Determinants of HIV-1 broadly neutralizing antibody induction.

Determinants of HIV-1 broadly neutralizing antibody induction.

Journal: Nature medicine

Published: March 01, 2016

Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.

Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.

Journal: PLoS pathogens

Published: January 19, 2015

High-throughput sequencing of human immunoglobulin variable regions with subtype identification.

High-throughput sequencing of human immunoglobulin variable regions with subtype identification.

Journal: PloS one

Published: May 27, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026